Rock Edwin's Form 4 filing
Crescent Biopharma, Inc.CBIO · filed Jun 24, 2024
- Accession no.
- 0001415889-24-017978
- Filed
- Jun 24, 2024, 4:29 PM ET
- Trade date
- Jun 20-21, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $78.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rock EdwinCIK 0001945417 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.